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OBJECTIVES: The number of bariatric procedures has significantly increased in Brazil, especially in the public
Unified Health System. The present study describes health outcomes and medication use in obese patients
treated in a major hospital that performs publicly funded surgery in Brazil.
METHODS: A retrospective, single center study was conducted to collect real-world evidence of health outcomes
and medication use in 247 obese patients (female, 82.2%) who underwent open Roux-en-Y gastric bypass.
Changes in weight and body mass index (BMI), presence of apnea, hypertension, and type 2 diabetes (T2D), and
medication use (hypertension, diabetes, and dyslipidemia) were assessed preoperatively and up to 24 months
postoperatively. The mean cost of medications was calculated for the 12-month preoperative and 24-month
postoperative periods.
RESULTS: During the surgery, the mean age of patients was 43.42 years (standard deviation [SD], 10.9 years),
and mean BMI was 46.7 kg/m2 (SD, 6.7 kg/m2). At 24 months, significant declines were noted in weight (mean,
-37.6 kg), BMI (mean, -14.3 kg/m2); presence of T2D, hypertension, and apnea (-29.6%, -50.6%, and -20.9%,
respectively); and number of patients using medications (-66.67% for diabetes, -41.86% for hypertension, and
-55.26% for dyslipidemia). The mean cost of medications (total costs for all medications) decreased by450% in
12–24 postoperative months compared to that in 12 preoperative months.
CONCLUSION: Roux-en-Y gastric bypass successfully reduced weight, BMI, and comorbidities and medication use
and cost at 24 months in Brazilian patients treated in the public Unified Health System.
KEYWORDS: Open Roux-en-Y Gastric Bypass; Healthcare Costs; Real-World Evidence; Delivery of Healthcare.
’ INTRODUCTION
There is consistent evidence that surgical treatment of obesity
results in more favorable weight loss and weight-associated
comorbidity outcomes compared with nonsurgical interven-
tions (1,2), with a positive impact on preexisting diabetes and
hypertension, among others (3,4). A lower risk of developing
type 2 diabetes (T2D), hypertension, angina, myocardial
infarction, and obstructive sleep apnea after bariatric surgery
has also been reported (4). The improvement or resolution of
comorbidities is likely to entail reduced medication use and
expenditure following bariatric surgery (3).
In 2014, Brazil was second only to the United States in
the number of bariatric/metabolic surgical procedures, with
495,000 surgeries in the country (5). In fact, Brazil has wit-
nessed a steady growth in the number of bariatric proce-
dures, especially in the public Unified Health System (SUS)
(6,7). Previous studies on the Brazilian population have
focused on some aspects of medication use and cost, inclu-
ding assessments before and after bariatric surgery (3) and
impact of surgery on metabolic syndrome components and
associated medications (8). However, these studies reported
extremely short-term results only, at 6 and 2 postoperative
months, respectively. A historical cohort on patients with
private health insurance who were analyzed 1 year before
and 1 year after bariatric surgery to determine cost and use
of healthcare services (9) did not include information onDOI: 10.6061/clinics/2020/e1588
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medication use, since medications are typically paid out of
pocket by these patients in Brazil. Other studies with follow-
up ranging from 12 months to 10 years (10-13) have provided
only limited information on medication use and no infor-
mation on medication cost or included cost of medications
only as part of a composite variable.
Therefore, this study aimed to describe health outcomes
and medication use from waitlisting for bariatric surgery
until 24 months postoperatively in obese patients treated in a
major hospital providing public healthcare in Brazil.
’ MATERIALS AND METHODS
We performed a retrospective, single-center study to
collect real-world evidence of health outcomes and medica-
tion use following gastric bypass. Medical records were
reviewed to identify eligible patients, and data covering the
period from wait listing for bariatric surgery (baseline) up to
24 months postoperatively were collected. The following
variables were assessed preoperatively and at 6, 12, and
24 months postoperatively: weight and body mass index
(BMI), presence of comorbidities (apnea, hypertension, T2D),
and medication use (hypertension, T2D, and dyslipidemia).
The mean cost of medications was calculated for the period
of 12 months preoperatively and 0–12 and 12–24 months
postoperatively. The mean cost of medications used during
the entire 24-month follow-up was also calculated. The price




The study was performed at Hospital das Clínicas de São
Paulo, a university hospital providing publicly funded care.
Adult patients undergoing SUS-reimbursed open Roux-en-Y
gastric bypass from January 2010 to July 2012 were eligible
for the study. The inclusion criteria were availability of 24-
month postprocedure follow-up data, ageX18 top65 years,
and BMI X40 kg/m2 (not responding to conservative treat-
ment for at least 2 years or having a life-threatening condi-
tion resulting from comorbidities) or BMIX35 mg/m2 in the
presence of at least one severe comorbidity associated with
obesity (hypertension, diabetes, etc.) (14,15), as determined
by the Brazilian Public Health Guidelines at the time the
study was conducted.
The exclusion criteria were pregnancy, Roux-en-Y gastric
bypass performed for revision or with other surgical
procedures (multiple surgeries) except for cholecystectomy
(e.g., colectomy or procedures not related to the bypass),
other types of bariatric surgery (gastric banding, sleeve
gastrectomy, etc.), and initial indication for other bariatric
procedures subsequently converted to Roux-en-Y gastric
bypass. The presence of the following conditions was also an
exclusion criterion: advanced cancer, HIV, viral hepatitis,
drug abuse, car accident, participation in interventional cli-
nical trials affecting treatment standards and use of resources
during the study period, and loss to postoperative follow-up.
Statistical analysis
For numerical variables, the Shapiro-Wilk normality test
was first applied to test if variables followed a normal dis-
tribution. Data that followed a normal distribution were
presented as means and standard deviation. Other data were
presented as median and interquartile interval. Categorical
variables were expressed as number and percentage (exclud-
ing missing data).
To conduce the analyses, data cleaning was previously
required. In this process, missing data were identified and
excluded from the analysis. For weight measurement, mis-
sing data were identified in 1 observation during surgery,
32 at 6 months, 21 at 12 months, and 19 at 24 months (repre-
senting 32 missing observations during surgery vs. 6 months,
21 during surgery vs. 12 months, and 19 during surgery vs.
24 months). In the variables that indicate the presence of
comorbidities, 18 missing observations were found for sleep
apnea (9 missing observations at 6 months, 6 at 12 months,
and 3 at 24 months postoperatively). For T2D and hyperten-
sion, 19 missing observations were identified (9 missing
observations at 6 months, 7 at 12 months, and 3 at 24 months,
postoperatively). For medication use and cost, no missing
variables were found.
All analyses conducted in this study aimed to evaluate the
variation in BMI, weight, cost, medication use, and comor-
bidities between the baseline and postoperative periods
(6, 12, and 24 months). After the analysis of the results through-
out the follow-up period, a post hoc analysis was conducted
to test the differences during surgery and each of the three
follow-up periods (6, 12, and 24 months postoperatively).
To evaluate the variation in weight and BMI during the
follow-up, the Shapiro-Wilk normality test was used, and
nonparametric tests were selected given the non-normality of
data. The Friedman test was initially conducted to identify if
weight differed across the periods (during surgery and after
6, 12, and 24 months), and post-hoc pairwise test was applied
to identify if variables during surgery and in each of the
follow-up periods were statistically significantly different.
To determine the presence of comorbidities in each period
(during surgery and after 6, 12, and 24 months), a contin-
gency table was created for three common diseases associa-
ted with BMI: T2D, hypertension, and sleep apnea.
To evaluate the difference in the use of medication pre- and
postoperatively, a contingency table was made, taking into
account the possible changes in intake doses of each patient.
Subsequently, the Cochran’s Q test was utilized to determine if
the differences were statistically significant. The post hoc
McNemar pairwise test was then applied to determine which
two-period comparison had different medication proportions.
In the cost analysis, the price of each medication was
selected from the Health Prices Database (Banco de Prec¸os
em Saúde), a system created by the Brazilian Ministry of
Health to record information on public and private pur-
chases of medications and health products. The cost of each
medication for every patient was then calculated, consider-
ing that the same patient could take different doses of the
same medication. After calculating the cost of each medica-
tion in the database (29 drugs), the cost for each patient was
then derived as the sum of every medication. The mean cost
for each period was obtained using total patients and costs.
Then, the Friedman test was conducted to determine if the
mean cost of medication was statistically significantly different
between periods, and the post-hoc pairwise Wilcoxon test
was conducted to identify if there are significant differences
between surgery and each follow-up period.
’ RESULTS
Of 259 potentially eligible patients, 247 fulfilled the inclusion
and exclusion criteria and were finally included. The reasons
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for exclusions were o24 months of follow-up data (N=7) and
age outside the predetermined range (N=5). The sample
included 203 women (82.18%).
The mean waiting time from baseline to surgery was
1,224 days (SD, ±297.77). The characteristics of the sample
at baseline and during surgery are presented in Table 1.
A median weight loss of 6 kg was found at baseline and
during surgery, with a median BMI decline of 2.205 kg/m2.
Weight and BMI decreased steadily throughout the study
(Figure 1). At 24 months, a median decrease in weight and
BMI of 38 kg and 14.86 kg/m2, respectively, was observed
(31.45% in relation to that during surgery, for both variables).
The decrease in weight and BMI was more pronounced
12 months postoperatively.
Comorbidities and medication use
During surgery, in 247 patients, T2D was present in 88
(35.6%), hypertension in 164 (66.4%), and apnea in 91 (36.8%).
A marked decrease in the presence of comorbidities was
observed at 24 months (Figure 2), with relative reduction rates
at 24 months vs. during surgery of 29.5% for T2D, 50.6% for
hypertension, and 20.9% for apnea.
The number of patients using medications to treat T2D,
hypertension, and dyslipidemia also significantly decreased
in the study period (Table 2): a 66.7% decrease was noted in
the number of patients using medications for T2D at 24 months
vs. baseline; the decrease was 41.9% for those for hypertension
and 55.3% for those for dyslipidemia. The mean cost of medi-
cations (considering the total costs for all medications used
to treat T2D, hypertension, and dyslipidemia) decreased by
450% from 12 preoperative months until 12–24 postoperative
months (Table 3).
’ DISCUSSION
The present study analyzed the 24-month results of 247
patients undergoing bariatric surgery in the public health-
care system in Brazil, showing a steady decline in weight,
presence of comorbidities, and number of patients using
medications in the observation period. As previously shown
(16), the number of studies reporting long-term results of
bariatric surgery, regardless of the technique used, is still
limited, with most reporting follow-ups of o2 years. In that
sense, the present results provide valuable real-world evi-
dence of the maintenance of favorable outcomes 24 months
postoperatively in a public healthcare system. This is espe-
cially important given the difficulty in consistently following
patients outside structured trials (11). Our findings are also
consistent with those reported by a recent study describing
the long-term (7 years) weight change and health status
following Roux-en-Y gastric bypass and laparoscopic adjus-
table gastric banding (17), which show sustained weight
loss and comorbidity remission specifically with bypass
procedures.
Table 1 - Characteristics of patients undergoing gastric bypass in
the public healthcare system, Hospital das Clı´nicas de Sa˜o Paulo,
Brazil, in 2010–2012.
Variable Baseline Surgery
Age in years, mean (SD) 41.31 (10.9) 43.42 (10.9)
Female sex, n (%) 203 (82.2) 203 (82.2)
Body mass index (kg/m2), median (IQR) 48.41 (7, 56) 46.22 (7, 38.7)
Presence of comorbidities, n (%)
Type 2 diabetes 81 (32.8) 88 (35.6)
Hypertension 160 (64.8) 164 (66.4)
Apnea 84 (34.0) 91 (36.8)
Medication use, n (%)
Type 2 diabetes 59 (23.9) 60 (24.3)
Hypertension 132 (53.4) 141 (57.9)
Dyslipidemia 33 (13.4) 38 (15.4)
Figure 1 -Median weight loss and BMI decline at 24 months in patients undergoing gastric bypass within the public healthcare system,
Hospital das Clı´nicas de Sa˜o Paulo, Brazil, in 2010–2012. po0.001 (Friedman test). During surgery vs. after 6, 12, and 24 months;
po0.001 (Wilcoxon test). Values for weight (kg): 122 during surgery; 93 after 6 months; 83.50 after 12 months; 83 after 24 months.
Values for BMI (kg/m2): 46.22 during surgery; 35.27 after 6 months; 31.90 after 12 months; 31.55 after 24 months.
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Because of the well-known relationship between obesity
and several debilitating health conditions (2), such as dia-
betes, whose control is still largely pharmacological, we also
investigated the use and cost of medications before and after
bariatric surgery. Although a dramatic decrease in the num-
ber of patients using medications was noted (66.7%, 41.9%,
and 55.3% for T2D, hypertension, and dyslipidemia medica-
tions, respectively), the straightforward savings calculated in
Brazilian currency were insignificant in contrast to the cost of
surgery. This might be related to the fact that these surgeries
were performed in the public healthcare system in Brazil,
in which the cost of prescription medications is unusually
low, since newer drugs, such as medications from the DPP-4,
GLP-1, and SGLT-2 classes, and newer insulins are not reim-
bursed by the public healthcare system. However, for
individuals who rely on private healthcare insurance (does
not cover medication expenses), the decrease in the need for
medications might translate into real savings. This might also
be the case in other countries or healthcare systems where
newer and more expensive drugs are employed. It is note-
worthy that Kelles et al. (9) reported a mean cost of US$
3,227.16 for bariatric surgery in the private healthcare system
in Brazil vs. US$ 1,380.74 for the same open surgery in the
SUS.
Moreover, as reported by Larsen et al. (18), results on the
ability of bariatric surgery to generate healthcare savings are
inconsistent. In their study, the authors investigated the
impact of bariatric surgery on healthcare costs, social transfer
payments, and income in a surgical vs. nonsurgical group in
7 years (3 years preoperatively, year of surgery, and 3 years
postoperative) in Denmark. The authors concluded that none
of these aspects were affected by bariatric surgery. However,
the cost of medications was significantly lower in the surgical
group, especially that of antidiabetic medications. Another
Figure 2 - Presence of comorbidities during gastric bypass and 6, 12, and 24 months postoperatively in patients treated in the public
healthcare system, Hospital das Clı´nicas de Sa˜o Paulo, Brazil, in 2010–2012. po0.001 (McNemar) during surgery vs. after 6, 12, and
24 months. SAH, systemic arterial hypertension; T2D, type 2 diabetes. Values for T2D: 34.82% during surgery; 19.43% after 6 months;
15.38% after 12 months; 10.53% after 24 months. Values for hypertension: 66.40% during surgery; 50.20% after 6 months; 43.72%
after 12 months; 33.60% after 24 months. Values for apnea: 36.84% during surgery; 17.81% after 6 months; 11.33% after 12 months;
7.69% after 24 months.
Table 2 - Use of medications before and after gastric bypass in patients treated within the public healthcare system, Hospital das
Clı´nicas de Sa˜o Paulo, Brazil, in 2010–2012.
Patients using medication for
Type 2 diabetesab Hypertensionab Dyslipidemiaac
Time pointd n (%)
% variation
since baseline n (%)
% variation
since baseline n (%)
% variation
since baseline
During surgery 60 (24.3) - 141 (57.1) - 38 (15.4) -
After 6 months 27 (10.9) -55.0 161 (46.9) -17.7 28 (11.3) -26.3
After 12 months 22 (8.9) -63.3 98 (39.7) -30.5 19 (7.7) -50.0
After 24 months 20 (8.1) -66.7 78 (33.2) -41.9 17 (6.9) -55.3
apo0.001 for type 2 diabetes, hypertension, and dyslipidemia (Cochran’s Q test).
bpo0.001 (post hoc McNemar) during surgery vs. after 6, 12, and 24 months.
cpo0.01 during surgery vs. after 6 months; po0.001 (post hoc McNemar) during surgery vs. after 12 and 24 months.
dPatients using medications during surgery and 6, 12, and 24 months postoperatively.
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study from Denmark (19) found large reductions in treat-
ment of metabolic syndrome-related conditions and use of
inhalants for obstructive airway diseases and glucocorticoid
3 years after gastric bypass, with increase in the use of neuro-
psychiatric drugs. Regardless of the increased use of some
drugs, these findings underscore the positive clinical impact
of bariatric surgery, which might be difficult to translate into
measurements of direct health costs; the metabolic benefits of
weight loss per se should not be overlooked. Additionally,
specific characteristics of different countries and healthcare
systems might also play a role in the cost, savings, and imp-
rovement in bariatric surgery.
An aspect that deserves to be explored further in future
studies is the quality of life (QoL) following gastric bypass.
In Brazil, preliminary results from the state of Goiás show
improvement in QoL following gastric bypass in 50 patients
followed for a minimum of 3 months (n=14) and maximum
of 4100 months (n=3) (13). Moreover, a systematic review
(20) of prospective studies (most of which had fair to good
methodological quality) showed a significant short- and
long-term increase in QoL after bariatric surgery. However,
the authors revealed that the questionnaires used for assess-
ment are too general, complicating the association of QoL
results with medical benefits.
The present study also included publicly treated patients
facing a multiyear wait before the bariatric procedure. The
recorded waiting period of approximately 3 years is typi-
cal for the SUS (21). In Canada, a recent study indicates a
waiting time of 412 months between referral and specialist
consultation plus an additional 6–18 months until surgery
(22), which could translate into comparable wait times.
Nevertheless, the health status of our sample was worse than
that of patients treated by the Ontario Bariatric Network,
with similar age (44.6 vs. 43.2 years in Ontario vs. São Paulo)
and proportion of women (81.9% vs. 82.18%) – with our
patients showing a fairly higher rate of obstructive sleep
apnea, diabetes, and hypertension (30.9%, 29.6%, and 27.2%
in Ontario vs. 36.8%, 35.6%, and 66.4% in São Paulo) (23). It
should be noted that we detected an increase in the number
of patients with T2D, hypertension, and apnea and those
using medications between waitlisting and surgery.
Despite the poor health status of our sample and the
deleterious effects possibly associated with long waits for
surgery (24), the 24-month results we obtained were satis-
factory. Among other aspects, this might reflect the experi-
ence of the surgical team in São Paulo, since the learning
curve for proficiency in bariatric surgery has been especially
challenging, with one study claiming a threshold of 100 cases
(25) and a more recent study from the state of Rio de Janeiro
(providing mixed private and public healthcare) established
a cutoff as 500 cases (26).
Some limitations of the present study must be acknowl-
edged. Given the specific patient management system used by
the study center, the pre- and postoperative status of patients
may not be generalizable to other populations. Furthermore,
the quality of the information collected may have been
compromised by the absence of control mechanisms in clinical
practice, a limitation inherent to the retrospective design.
Finally, the measurement of medication costs alone is not
sufficient to draw conclusions regarding economic advantages
of bariatric surgery in the healthcare system.
’ CONCLUSIONS
The present 24-month follow-up of patients treated in
the public healthcare system in Brazil shows that gastric
bypass is an advantageous procedure that results in signi-
ficant weight loss. The presence of diabetes, hypertension,
and apnea decreased in association with gastric bypass, as
did medication use. A significant decrease was also observed
for the cost associated with medications. Further studies
should focus on longer follow-ups and comprehensive social
and economic assessments of the contribution of gastric
bypass to the healthcare system.
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Table 3 - Mean cost of medications before and after gastric
bypass in patients treated within the public healthcare system,
Hospital das Clı´nicas de Sa˜o Paulo, Brazil, in 2010–2012.
Mean cost of medicationsa
Time intervalbc R$ (SD) per patient
12 months preop 151.81 (236.98)
0–12 months postop 86.53 (236.67)
12–24 months postop 66.19 (131.05)
0–24 months postop 76.36 (118.28)
aMean cost of all medications used by patients 12 months preoperatively,
0–12 months and 12–24 months postoperatively, and for the entire
postoperative period of 24 months. 1.00 USD = 3.86 BLR.
bpo0.001 (Friedman test).
cpo0.001 for 12 months preoperatively vs. 0–12 months, 12–24 months,
and 0–24 months postoperatively (Wilcoxon test).
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